The company operates a hub-and-spoke laboratory network using massive regional labs for high-volume testing and smaller rapid response labs for urgent hospital needs. While competitors like Labcorp focus on drug development, Quest has doubled down on being a pure-play diagnostic leader, maintaining a slight edge in physician-office outreach and hospital partnerships.
Cyborg Score Rationale
As of February 11, 2026, Quest Diagnostics is trading near its all-time high, with the stock climbing roughly 22% over the past 12 months. By successfully marrying traditional lab volume with cutting-edge advanced diagnostics and AI, the company has proven it can grow in a challenging macro environment.
Top Insights
Project Nova modernization strategy positioning Quest for advanced diagnostics and AI-driven efficiency growth